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OBJECTIVES: Hepatocellular carcinoma (HCC) is the ﬁfth cause of dead from cancer 
worldwide. Hepatitis B virus infection is the important risk of HCC. Alpha fetoprotein 
(AFP) and liver ultrasound had been introduced as semi-annual screening test for HCC 
in human with hepatitis B surface antigen positive or patients with chronic hepatitis 
B. However, the cost-effectiveness of this screening is not well deﬁned. Our objective 
was to explore the cost-effectiveness of semi-annual HCC screening using AFP and 
liver ultrasound from societal perspective compared with no screening. METHODS: 
With a Markov model, we simulated the four health states of natural history of HCC 
which were no HCC state, resectable HCC state, unresectable HCC state and death 
state with 6-month cycle lenght. The based case decision model was run for male 
patients with age of 51 that is mean age of screening group. Cost and outcomes were 
discounted at a 3% annual rate. Probabilistic sensitivity analysis was performed. 
RESULTS: For semi-annual HCC screening, the incremental cost effectiveness ratio 
(ICER) which compared with no screening was US$14,111 (95%CI US$13,650–
US$14,573) per quality adjusted life year (QALY) for male chronic HBV patients. 
CONCLUSIONS: AFP with liver ultrasound is not cost effective for semi-annual 
screening HCC in patients with hepatitis B surface antigen positive or patients with 
chronic hepatitis B, according to the Thai threshold that ICER of cost-effective inter-
vention should not be exceed US$ 9000 per QALY.
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OBJECTIVES: New treatments for advanced NSCLC offer clinical beneﬁts over 
standard chemotherapy, however it is important they demonstrate value for money. 
Bevacizumab with chemotherapy improves survival and time to progression in patients 
with advanced NSCLC compared to chemotherapy alone. Pemetrexed and cisplatin 
has shown survival improvements over gemcitabine plus cisplatin. In the light of 
gemcitabine generic pricing, the aim of this analysis was to provide an update on how 
the treatment costs of bevacizumab plus cisplatin and gemcitabine (BCG) compare 
with pemetrexed plus cisplatin (PC) therapy in Germany. METHODS: A 3-state 
Markov model was used to evaluate the costs of treating advanced or recurrent 
NSCLC with either BCG or PC induction therapy. The model assumes patients move 
between states according to transition probabilities derived from the efﬁcacy data 
(progression-free survival) from the pivotal trials. Drug costs assume chemotherapy 
was given for up to 6 cycles, but that single agents pemetrexed and bevacizumab 
(7.5 mg/kg) were administered until progression. RESULTS: The monthly drug costs 
for BCG and PC therapy were 35764 and 36456, respectively; a saving of 3692 per 
month with BCG. The mean monthly costs of administration were 3205 for BCG and 
3153 for PC (a difference of 352). CONCLUSIONS: With the availability of generic 
gemcitabine during 2009, triplet therapy with bevacizumab has increased the potential 
monthly cost savings compared to doublet chemotherapy with pemetrexed. From a 
budget perspective bevacizumab should be considered as the targeted therapy of choice 
for patients with advanced NSCLC in Germany.
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OBJECTIVES: The aim of present analysis was to assess cost-effectiveness of leno-
grastim in comparison with other G-CSFs—ﬁlgrastim and pegﬁlgrastim in Polish 
settings (threshold is about 100,095 PLN). METHODS: Analysis covered time horizon 
of one chemotherapy cycle. A public payer perspective was adopted for cost analysis. 
The costs included were based on Polish NHF reference costs list. Data on time to 
ANC recovery, number of days with fever, length of hospital stay and antibiotics use 
were obtained from randomized controlled trials (RCTs) identiﬁed in the conducted 
systematic review. These included trials on prophylactic G-CSF use as well as trials in 
which only patients with neutropenia were included. Equations describing costs and 
QALY according to neutropenia and fever length, hospital stay and antibiotic use were 
established. RESULTS: Estimated QALY difference between lenograstim and ﬁlgras-
tim is 0.0035 (CI95%[0.0023; 0.0048]), compared to pegﬁlgrastim is 0.0039 
(CI95%[0.0026; 0.0052]). Total costs difference between lenograstim and ﬁlgrastim is 
−2015 PLN (CI95%[−3004; −938]) and compared to pegﬁlgrastim is −3236 PLN 
(CI95%[−4125; −2259]). Probability of lenograstim being cost-effective over ﬁlgrastim 
is 99.98% and over pegﬁlgrastim is 100%. Taking into account only trials where 
G-CSFs were used in neutropenia prophylaxis estimated QALY difference between 
lenograstim and ﬁlgrastim is 0.0029 (CI95%[0.0015; 0.0044]), compared to pegﬁlgras-
tim is 0.0031 (CI95%[0.0017; 0.0047]). Total costs difference between lenograstim and 
ﬁlgrastim is −1720 PLN (CI95%[−2935; −487]) and compared to pegﬁlgrastim is −3097 
PLN (CI95%[−4168; −1943]). Probability of lenograstim being cost-effective over ﬁl-
grastim is 99.81% and over pegﬁlgrastim is 100%. CONCLUSIONS: Lenograstim is 
dominant over ﬁlgrastim and pegﬁlgrastim. Acknowledgements: This analysis was 
supported by Sanoﬁ-Aventis.
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OBJECTIVES: To conduct a cost effectiveness analysis of anti-EGFR treatment 
regimes for the treatment refractory mCRC. Clinical trial data was available and 
utilized to examine panitumumab monotherapy and to compare cetuximab mono-
therapy vs cetuximab + irinotecan therapy, while indirect clinical trial data compared 
cetuximab based therapies with panitumumab monotherapy. METHODS: A Markov 
model comprising of three health states (stable disease, progressive disease and death), 
was developed from an US societal perspective to estimate economic implications of 
weekly anti-EGFR treatments for 52 weeks for 1000 treatment refractory mCRC 
patients. Transition probabilities were estimated based on available clinical literature 
data for each treatment. Therapy cost, health utilities, direct and indirect costs were 
based on published literature and national health care databases. Cost parameters 
were reported based on 2009 US dollars with a 3% discount rate. RESULTS: The 
analyses yielded an ICER of $249,035/QALY for cetuximab monotherapy vs cetux-
imab + irinotecan, an ICER of $266,196/QALY for cetuximab monotherapy vs. 
panitumumab, an ICER of $250,992/QALY for cetuximab + panitumumab and an 
ICER of $773,978/QALY for panitumumab vs. best supportive care (placebo). 
Through strictly increasing rankings of the ICERs, we ﬁnd best supportive care to be 
most cost effective therapy, followed by panitumumab monotherapy, cetuximab 
monotherapy and cetuximab + irinotecan therapy; however, changes in model param-
eters may inﬂuence the rankings of the treatment regimes. CONCLUSIONS: Based on 
the willingness to pay threshold of $150,000/QALY, treating treatment refractory 
mCRC patient with anti-EGFR agents is not cost effective. However, since the clinical 
literature lacks comprehensive head to head clinical trial amongst all anti-EGFR 
agents, further research is necessary.
PCN85
ECONOMIC MODELING FOR TREATMENT FAILURE PATIENTS USING 
MULTIPLE ROUNDS OF THERAPY AS COMPARATOR: CASE IN POINT 
LYMPHOMA DRUG CANDIDATE
Aggarwal S1, White N2, Stevens CA3
1PAREXEL Consulting, Bethesda, MD, USA, 2PAREXEL Consulting, Centreville, VA, USA, 
3PAREXEL Consulting, Waltham, MA, USA
OBJECTIVES: Treatment failure patients in various disease areas are often treated by 
multiple rounds of therapy. However new treatment options are emerging that have 
potential to replace that treatment with single-agent or single round of combination 
treatment. It is challenging to demonstrate cost effectiveness of these new agents, 
especially when comparator is not one single regimen but sequential treatment. We 
present here our results from a study where we developed a model that can incorporate 
multiple rounds of treatment or relapses to estimate cost effectiveness of new emerging 
therapies. METHODS: Intervention was chosen as an emerging T-cell lymphoma drug 
candidate. Comparator was chosen as sequential treatment with 1–5 chemo regimens 
(called DHAP, ESHAP, ICE, HyperCVAD and EPOCH). All comparator chemo regi-
mens are generics and their prices were obtained from Medispan’s PriceRx. Interven-
tion’s price was assumed as median price of branded chemotherapy agents. Cost, 
efﬁcacy, adverse events and utilities were sourced and estimated from published studies 
for T and B-cell lymphoma. Relapses and number of chemo regimens for comparators 
were varied from 1–5. Sensitivity analyses were performed for all base calculations. 
RESULTS: Model results show that a new agent that can replace multiple rounds of 
treatment is relatively more cost effective that another agent that replaces relatively 
fewer rounds of treatments. Our base case incremental cost effectiveness with one 
chemo regimen as comparator was $262,908. However if there are 2,3,4 or 5 sequen-
tial rounds, the ICER values change to $223,078, $183,249, $143,420, and $103,591, 
respectively. CONCLUSIONS: For newer agents that are indicated for treatment 
failure patients, the use of sequential treatments as comparator can signiﬁcantly 
improve their cost effectiveness. The model approach described here can be used for 
Arthritis, Hepatitis C, and Diabetes and Oncology TF patients.
